Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a global prevalence estimated at approximately 25%. NAFLD is also the leading cause of liver cirrhosis, hepatocellular carcinoma, and death. Additionally, the risk of cardiovascular disease increases with greater NAFLD severity. The liver- and cardiovascular disease-related mortality incident rate ratios among the NAFLD population were 0.77 and 4.79 per 1,000 person-years, respectively. We intend to discuss the risk factors associated with NAFLD in terms of development and progression. Obesity or higher body mass index is closely associated with NAFLD in a dose-dependent manner, but growing evidence suggests that central obesity plays a more important role in the development of NAFLD. Saturated fat and fructose have been reported to be closely related to NAFLD. Fructose intake promotes lipogenesis and impairs mitochondria fat oxidation. The presence of type 2 diabetes is the most powerful predictive risk factor for hepatic fibrosis in patients with NAFLD. Single nucleotide polymorphism is not only associated with the prevalence of NAFLD but also associated with increased liver disease mortality. Obstructive sleep apnea, intestinal dysbiosis, and sarcopenia are associated with the development of NAFLD
Citations
Citations to this article as recorded by
Quantitative Liver Fat Assessment by Handheld Point-of-Care Ultrasound: A Technical Implementation and Pilot Study in Adults Dorathy Tamayo-Murillo, Jake T. Weeks, Cody A. Keller, Michael Andre, Celene Gonzalez, Andrew Li, Eduardo Grunvald, Joy Liau, Sedighe Hosseini Shabanan, Tanya Wolfson, Jingyi Zuo, Adam Robinson, Carolina Amador Carrascal, Nevada Sanchez, Scott B. Reeder, Ultrasound in Medicine & Biology.2025; 51(3): 475. CrossRef
Decompensated Cirrhosis with Hepatopulmonary Syndrome in a Patient with Interrupted Treatment for Hypopituitarism Tomoko Tadokoro, Joji Tani, Yudai Sato, Rie Yano, Kei Takuma, Mai Nakahara, Kyoko Oura, Koji Fujita, Masafumi Ono, Atsushi Tobiume, Seisuke Sato, Takuya Inoue, Asahiro Morishita, Hideki Kobara Internal Medicine.2025; 64(15): 2307. CrossRef
Smoking and Risk of Fatty Liver Disease: A Meta-Analysis of Cohort Studies Moonhyung Lee, Seung-Kwon Myung, Sang Hee Lee, Yoosoo Chang Gastroenterology Insights.2025; 16(1): 1. CrossRef
Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang European Journal of Gastroenterology & Hepatology.2025; 37(5): 652. CrossRef
Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis Gina Ryu, Eileen Laurel Yoon, Wankyu Kim, Dae Won Jun Diagnostics.2025; 15(3): 342. CrossRef
A novel 11β-HSD1 inhibitor ameliorates liver fibrosis by inhibiting the notch signaling pathway and increasing NK cell population Ji Eun Kim, Yun Kim, Jiwon Bae, Eileen Laurel Yoon, Hyun Sung Kim, Sung Ryol Lee, Tae Hyun Yoon, Dae Won Jun Archives of Pharmacal Research.2025; 48(2): 166. CrossRef
Transcriptomic analysis reveals the mechanisms underlying the differential effects of caffeine, theophylline, and theobromine in regulating hepatic fat accumulation Jinya Dong, Xiaocui Du, Ruijuan Yang, Linxian Shan, Xiuli Lu, Yan Shen, Yanmei Li, Shengjie Duan, Zezhu Du, Jianyang Fu, Jun Sheng, Chongye Fang Food & Function.2025; 16(6): 2503. CrossRef
Epidemiological Dynamics of Burden and Health Inequalities in Metabolic Dysfunction-associated Steatotic Liver Disease in Adolescents at Global, Regional, and National Levels, 1990–2021 Xiaohui Sui, Junde Zhao, Yuxin Yang, Yikun Yang, Kaifeng Li, Zuocheng Wang, Ziqi Liu, Ruining Lu, Guiju Zhang Journal of Clinical and Experimental Hepatology.2025; 15(4): 102537. CrossRef
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S Hepatology International.2025; 19(2): 261. CrossRef
Editorial: Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Hyo Young Lee, Dae Won Jun Alimentary Pharmacology & Therapeutics.2025; 61(9): 1545. CrossRef
Non-alcoholic fatty liver disease: diet therapy and pharmacotherapy M. L. Maksimov, V. A. Dudareva, V. O. Vovk, V. I. Sklyarova, S. O. Ivashchenko, A. A. Shikaleva Terapevt (General Physician).2025; (3): 37. CrossRef
Serum uric acid may be a mediator of risk factors in metabolic dysfunction associated steatotic liver disease Xueying Wang, Song Leng Scandinavian Journal of Gastroenterology.2025; 60(6): 581. CrossRef
Gut microbiota-derived metabolite phenylacetylglutamine in cardiovascular and metabolic diseases Wan Chen, Mei-Ling Li, Guang Zeng, Xiang-Yu Xu, Shan-Hui Yin, Can Xu, Linlin Li, Kaikai Wen, Xiao-Hua Yu, Gang Wang Pharmacological Research.2025; 217: 107794. CrossRef
Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up Mimi Kim, Huiyul Park, Eileen L. Yoon, Ramsey Cheung, Donghee Kim, Hye-Lin Kim, Dae Won Jun Scientific Reports.2025;[Epub] CrossRef
Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease Joo Hyun Oh, Eileen L. Yoon, Huiyul Park, Seungmin Lee, Ae Jeong Jo, Seon Cho, Eunjoo Kwon, Eun-Hee Nah, Jun-Hyuk Lee, Jung Hwan Park, Sang Bong Ahn, Dae Won Jun Journal of Hepatology.2025; 83(6): 1256. CrossRef
Pathogenic effects of telomerase reverse transcriptase (TERT) promoter mutations in nonalcoholic steatohepatitis (NASH) related hepatocellular carcinoma (HCC) and its potentials as a diagnostic biomarker Usman Umar Liman, Asanka Sudeshini Hawage, Sumadee De Silva, Saumya Madushani Samarasinghe, Kamani Hemamala Tennekoon, Rohan Chaminda Siriwardana, Madunil Anuk Niriella Egyptian Journal of Medical Human Genetics.2025;[Epub] CrossRef
Cadmium exposure and weight-adjusted waist index: Interactions with selenium in modulating hepatic fibrosis Chenggang Yang, Mengru Hao, Junying Zhu, Yutian Luo, Alexey A. Tinkov, Olga S. Ignatovets, Shimiao Dai, Zhan Shi, Yuqing Chen, Ji-Chang Zhou Food and Chemical Toxicology.2025; 204: 115613. CrossRef
High sensitivity C-reactive protein may be a significant predictor of non-alcoholic fatty liver disease in non-obese adults: A four-year retrospective study Changxi Chen, Jiande Gong, Mengting Li, Shiyu Pan, Guitao Xia, Yuemei Xu, Hongliang Li, Qi Lin Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(12): 104224. CrossRef
Association between waist circumference and fatty liver disease in older adult population: a cross-sectional study in Urumqi Mingdong Zhang, E. Zhao, Gaofeng Sun Frontiers in Public Health.2025;[Epub] CrossRef
Obstructive sleep apnea and metabolic-associated fatty liver disease risk: Insights from National Health and Nutrition Examination Survey and Mendelian randomization analysis Cao Beibei, Zhen Junhai, Tan Zongbiao, Peng Fang Nutrition, Metabolism and Cardiovascular Diseases.2025; : 104265. CrossRef
Tracking Mutual Interactions of Mitochondria/Lysosomes/Lipid Droplets in DILI and NAFLD with a Viscosity and Peroxynitrite-Sensitive Single Fluorescent Probe Chunhua Fan, Xionghao Xu, Bo Zhao, Tao Jiang, Tianxin Liu, Chaewoon Cho, Juyoung Yoon, Zhengliang Lu Analytical Chemistry.2025; 97(40): 21935. CrossRef
From steatosis to cirrhosis: the role of obesity in the progression of liver disease Klaudia Nowak, Maria Paluch, Maja Cudzik, Klaudia Syska, Wiktoria Gawlikowska, Jakub Janczura Journal of Diabetes & Metabolic Disorders.2025;[Epub] CrossRef
Allyl nonanoate as a novel bile-derived biomarker in metabolic dysfunction-associated steatotic liver disease Soo Hyeon Lee, Jonghwan Kim, Sung Ryol Lee, Bum Soo Lee, Ki Hyun Kim, Dae Won Jun, Chung Sub Kim, Kyung A Kang Frontiers in Endocrinology.2025;[Epub] CrossRef
Associations between metabolic score for visceral fat and nonalcoholic fatty liver disease (NAFLD) in US adults: A cross-sectional study based on NHANES 2017–2020 Juan Li, Shenglan Dai Medicine.2025; 104(46): e45082. CrossRef
Cardiac remodelling in novel cluster-based metabolic (dysfunction)-associated fatty liver disease: a cross-sectional study in China Yina Wang, Xiaolan Ouyang, Na Ye, Weilan Huang, Ying Zhou, Shangyan Liang, Sijing Luo, Xiumei Tang, Boxiong Jiang, Xixiang Tang BMJ Open.2025; 15(11): e102845. CrossRef
Association between dietary quality index – international (DQI-I) and fatty liver indices: results from the Ravansar non-communicable disease (RaNCD) cohort study Shaimaa A. Qaisar, Akram Rahiemi, Narges Shahnazi, Shahab Rezaeian, Mehdi Moradi Nazar, Jalal Moludi, Yahya Pasdar Scientific Reports.2025;[Epub] CrossRef
Association between serum trace element, mineral, and amino acid levels with non-alcoholic fatty liver disease (NAFLD) in adult women Alexey A. Tinkov, Tatiana V. Korobeinikova, Galina D. Morozova, Michael Aschner, Daria V. Mak, Abel Santamaria, Joao B.T. Rocha, Tatiana I. Sotnikova, Serafima Ia. Tazina, Anatoly V. Skalny Journal of Trace Elements in Medicine and Biology.2024; 83: 127397. CrossRef
Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunction-associated steatotic liver disease in postpartum women: A nationwide study Young Mi Jung, Seung Mi Lee, Wonyoung Wi, Min-Jeong Oh, Joong Shin Park, Geum Joon Cho, Won Kim JHEP Reports.2024; 6(4): 101033. CrossRef
Hybrid Quantum Image Classification and Federated Learning for Hepatic Steatosis Diagnosis Luca Lusnig, Asel Sagingalieva, Mikhail Surmach, Tatjana Protasevich, Ovidiu Michiu, Joseph McLoughlin, Christopher Mansell, Graziano de’ Petris, Deborah Bonazza, Fabrizio Zanconati, Alexey Melnikov, Fabio Cavalli Diagnostics.2024; 14(5): 558. CrossRef
Characterisation and beneficial effects of a Lupinus angustifolius protein hydrolysate obtained by immobilisation of the enzyme alcalase® Guillermo Santos-Sánchez, Ivan Cruz-Chamorro, José Carlos Márquez-López, Justo Pedroche, Ana Isabel Álvarez-López, María del Carmen Millán-Linares, Patricia Judith Lardone, Antonio Carrillo-Vico Food & Function.2024; 15(7): 3722. CrossRef
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences Joo Hyun Oh, Dae Won Jun Clinical and Molecular Hepatology.2024; 30(2): 168. CrossRef
Gestational supplementation of Bifidobacterium, Lactobacillus, and Streptococcus thermophilus attenuates hepatic steatosis in offspring mice through promoting fatty acid β‐oxidation Hangjun Chen, Qiongmei Wu, Xingyi Chen, Xinxue Yu, Hanqing Zhao, Qiaoli Huang, Yurong Huang, Jinting Wang, Xueyi Huang, Jun Wei, Feng Wu, Xiaomin Xiao, Lijun Wang Journal of Food Science.2024; 89(5): 3064. CrossRef
Polyethersulfone Polymer for Biomedical Applications and Biotechnology Monika Wasyłeczko, Cezary Wojciechowski, Andrzej Chwojnowski International Journal of Molecular Sciences.2024; 25(8): 4233. CrossRef
The gut-liver axis in fatty liver disease: role played by natural products Zhu Ming, Xie Ruishi, Xu Linyi, Yang Yonggang, Luo Haoming, Lan Xintian Frontiers in Pharmacology.2024;[Epub] CrossRef
Association between the skeletal muscle mass to visceral fat area ratio and metabolic dysfunction‐associated fatty liver disease: A cross‐sectional study of NHANES 2017–2018 Zhiliang Mai, Yinfei Chen, Hua Mao, Lisheng Wang Journal of Diabetes.2024;[Epub] CrossRef
Association between hemoglobin and non-alcoholic fatty liver disease (NAFLD) in United States adults: Results from NHANES 2017–2020 Kang Yao, Zheng Chen, Wei Zhou, Zhihua Liu, Wei Cui Preventive Medicine Reports.2024; 44: 102798. CrossRef
Metabolic dysfunction–associated fatty liver disease and osteoporosis: the mechanisms and roles of adiposity Jie Tao, Hong Li, Honggang Wang, Juan Tan, Xiaozhong Yang Osteoporosis International.2024; 35(12): 2087. CrossRef
Knowledge, Attitudes, and Determinants of Nonalcoholic Fatty Liver Disease Among Adults in Jazan Province: A Cross-Sectional Study Ali M Someili, Mostafa Mohrag, Bandar S Rajab, Abdulrahman A Daghreeri, Fawaz M Hakami, Riyadh A Jahlan, Abdulrahman A Otaif, Abdulelah A Otaif, Hussam T Hakami, Bandar F Daghriri, Ameer M Mobarki, Rakan B Almjlad, Mousa Mobarki Cureus.2024;[Epub] CrossRef
Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study” Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2024; 30(4): 1033. CrossRef
Silybin: A Review of Its Targeted and Novel Agents for Treating Liver Diseases Based on Pathogenesis Jijiao Wu, Lin Wen, Xiaolian Liu, Qiuxia Li, Zihao Sun, Chuipeng Liang, Fan Xie, Xiaofang Li Phytotherapy Research.2024; 38(12): 5713. CrossRef
Acute Toxicity and Hepatoprotective Influence of Hypericum perforatum Against Thioactamid-Induced Liver Fibrosis in Rats Ahmed A.J. Jabbar, Zaenah Zuhair Alamri Natural Product Communications.2024;[Epub] CrossRef
The Role of Dietary Ingredients and Herbs in the Prevention of Non-Communicable Chronic Liver Disease Monika Maćków, Tomasz Dziubyna, Tatiana Jamer, Dmytro Slivinskyi, Tomasz Pytrus, Katarzyna Neubauer, Małgorzata Zwolińska-Wcisło, Andrzej Stawarski, Ewa Piotrowska, Dorian Nowacki Nutrients.2024; 16(20): 3505. CrossRef
Phytochemical Profiling, Acute Toxicity, and Hepatoprotective Effects of Anchusa Limbata in Thioacetamide‐Induced Liver Cirrhosis in Rats Khaled Abdul‐Aziz Ahmed, Ahmed A. J. Jabbar, Mohammed M. Hussein M. Raouf, Ayman M. Al‐Qaaneh, Rawaz Rizgar Hassan, Musher Ismael Salih, Ramzi A. Mothana, Gadah Abdulaziz Al‐Hamoud, Mahmood Ameen Abdulla, Sidgi Hasson, Parween Abdul‐samad Ismail Food Science & Nutrition.2024; 12(12): 10628. CrossRef
Quantificação da gordura hepática: avaliação de diferentes estratégias de medidas pela ressonância magnética nos casos de distribuição homogênea e heterogênea Eloa de Castro Noguerol, Luis Ronan Marquez Ferreira de Souza, Valdair Francisco Muglia, Jorge Elias Jr. Radiologia Brasileira.2024;[Epub] CrossRef
Quantification of hepatic fat: evaluation of different magnetic resonance imaging measurement strategies in cases of homogeneous and heterogeneous distribution Eloa de Castro Noguerol, Luis Ronan Marquez Ferreira de Souza, Valdair Francisco Muglia, Jorge Elias Jr. Radiologia Brasileira.2024;[Epub] CrossRef
LDHA- Mediated Histone Lactylation Promotes the Nonalcoholic Fatty Liver Disease Progression Through Targeting The METTL3/ YTHDF1/SCD1 m6A Axis J Meng, C Yan, J Liu Physiological Research.2024; : 985. CrossRef
Optimal choice of diet and food for NAFLD G. V. Shavkuta, L. B. Lazebnik Experimental and Clinical Gastroenterology.2024; (10): 98. CrossRef
Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis Xiangyu Zhou, Jincheng Wang, Sufang Zhou, Jiajia Liao, Zuoyu Ye, Leiming Mao Medicine.2023; 102(4): e32734. CrossRef
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef
The growing burden of non-alcoholic fatty liver disease on mortality Ju-Yeon Cho, Won Sohn Clinical and Molecular Hepatology.2023; 29(2): 374. CrossRef
Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors? Heejoon Jang, Won Kim Clinical and Molecular Hepatology.2023; 29(2): 381. CrossRef
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef
Moderate- and High-Intensity Endurance Training Alleviate Diabetes-Induced Cardiac Dysfunction in Rats Sarah D’Haese, Maxim Verboven, Lize Evens, Dorien Deluyker, Ivo Lambrichts, BO Eijnde, Dominique Hansen, Virginie Bito Nutrients.2023; 15(18): 3950. CrossRef
Waiting for the changes after the adoption of steatotic liver disease Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 844. CrossRef
Letter regarding “Risk factors in nonalcoholic fatty liver disease” Abhijit Pratap, Umesh More, Pradnya Phalak, Anita Deshmukh Clinical and Molecular Hepatology.2023; 29(4): 1046. CrossRef
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe Clinical and Molecular Hepatology.2023; 29(4): 987. CrossRef
Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease” Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 1050. CrossRef
Association of fat-to-muscle ratio with non-alcoholic fatty liver disease: a single-centre retrospective study Fengqin Yan, Guqiao Nie, Nianli Zhou, Meng Zhang, Wen Peng BMJ Open.2023; 13(10): e072489. CrossRef
International diet quality index and revised diet quality index relationship with non-alcoholic fatty liver disease: a case-control study Narjes Najibi, Mitra Kazemi Jahromi, Farshad Teymoori, Hossein Farhadnejad, Ammar Salehi-Sahlabadi, Parvin Mirmiran BMC Gastroenterology.2023;[Epub] CrossRef
First
Prev
